SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?


To: Biotech Jim who wrote (2839)3/18/2013 9:55:22 AM
From: Watch_It_Drop  Read Replies (1) | Respond to of 3202
 
Does anyone in here take this opportunity to buy more?

Thanks!



To: Biotech Jim who wrote (2839)3/18/2013 9:57:22 AM
From: Biotech Jim  Read Replies (1) | Respond to of 3202
 
From the EMEA filing documents regarding CNS penetration of ruxolitinib (ie, Jakafi):

"Penetration of ruxolitinib and ruxolitinib-derived radioactivity into central nervous system tissues was limited (less than 10% of plasma concentration)."

ema.europa.eu

Just parking this info for further consideration.

BJ